[Pharmacologic and clinical properties of a new butyrophenone derivative (FR 33)].
D000328:Adult; D000661:Amphetamine / Q000037:antagonists & inhibitors; D000818:Animals; D000928:Antidepressive Agents / Q000494:pharmacology* / Q000627:therapeutic use; D002090:Butyrophenones / Q000494:pharmacology* / Q000627:therapeutic use; D002375:Catalepsy / Q000139:chemically induced; D002389:Catatonia / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D003672:Defecation / Q000187:drug effects; D003864:Depression, Chemical; D004924:Escape Reaction / Q000187:drug effects; D005260:Female; D006801:Humans; D008607:Intellectual Disability / Q000188:drug therapy; D008297:Male; D051379:Mice; D008875:Middle Aged; D009043:Motor Activity / Q000187:drug effects; D010301:Parkinson Disease, Postencephalitic / Q000188:drug therapy; D011600:Psychopharmacology; D051381:Rats; D012559:Schizophrenia / Q000188:drug therapy
D000928:Antidepressive Agents; D002090:Butyrophenones; D000661:Amphetamine
Pharmakologische und klinische Eigenschaften eines neuen Butyrophenon-Derivates(FR 33)